Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $55.75 USD
Change Today +1.67 / 3.09%
Volume 7.6M
TEVA On Other Exchanges
New York
Tel Aviv
As of 8:04 PM 02/12/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Basel Street

P.O. Box 3190

Petach Tikva, 49131


Phone: 972 3 926 7267

Fax: 972 3 923 4050

e Granulocyte Colony Stimulating Factor (G-CSF) medicines that stimulate the production of white blood cells and are primarily used to reduce the risk of infections in oncology patients receiving chemotherapy. Granix (short-acting G-CSF) is approved in the United States and is approved via a Biologics License Application by the FDA in 2012 and launched in 2013. The product is also approved and available in Japan and certain other Rest of the World (ROW) markets. In December 2014, the FDA also approved Granix injection for self-administration by patients and caregivers. Lonquex (long-acting G-CSF) is a G-CSF with the active ingredient lipegfilgrastim, a novel glycoPEGylated (PEG; polyethylene glycol) filgrastim molecule. Women’s Health The company’s women’s health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel), and Zoely along with other local products that are marketed in the United States, Europe and ROW. Plan B One-Step OTC/Rx (levonorgestrel) is an emergency oral contraceptive which consists of a single tablet dose of levonorgestrel for emergency contraception. ParaGard T380 A (intrauterine copper contraceptive) is a non-hormonal intrauterine contraceptive marketed in the United States. Other Activities The company’s other activities comprise its OTC business. Consumer Healthcare Joint Venture PGT Healthcare (PGT) is its consumer healthcare joint venture with The Procter & Gamble Company. The joint venture includes its OTC medicines and vitamins, minerals and food supplements (VMS). PGT manufactures and markets approximately 200 consumer healthcare brands in 70 countries worldwide. Its portfolio includes cough and cold brand Vicks, Germany’s OTC brand ratiopharm, and other brands. Strategy The company seeks to capitalize on its advantages, including the largest generic medicines business in the world, a focused specialty business, a unique OTC business and its integrated R&D and API capabilities to provide patients with integrated, outcome-focused solutions. The key elements of its strategy consist of the following: solidifying its foundation and driving organic growth; focusing on key growth markets; maintaining Copaxone and other key specialty products; solidifying leadership positions in core therapeutic areas; pursuing strategic business development initiatives; and executing on cost reduction program. Significant Events In April 2015, OncoGenex Pharmaceuticals, Inc. announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex would regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. In January 2016, Teva Pharmaceutical Industries and AbCellera have entered into a collaborative research agreement whereby AbCellera would apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies. History Teva Pharmaceutical Industries Limited was founded in 1901.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $55.75 USD +1.67

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $37.13 USD +0.79
AbbVie Inc $52.58 USD +0.40
AstraZeneca PLC 4,047 GBp +55.50
Biogen Inc $247.22 USD +2.11
Eli Lilly & Co $71.27 USD -0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation TEVA Industry Range
Price/Earnings 30.6x
Price/Sales 2.5x
Price/Book 1.6x
Price/Cash Flow 35.8x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TEVA PHARMACEUTICAL-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at